Mechanism of action, clinical trial references, and OSMF Evidence Tiers for therapeutic interventions in Long COVID / PASC, ME/CFS, POTS, and MCAS — synthesised from RCTs, systematic reviews, and peer-reviewed literature.
Current condition
Evidence-graded therapeutic interventions for Long COVID / PASC, synthesised from clinical trials, systematic reviews, and mechanistic studies.
Each agent entry includes a molecular-level mechanism description covering key targets, signalling pathways, and proposed disease-relevant mechanisms.
Assigned using the OSMF Evidence Tier framework — T1 = RCT in the target condition; T6 = mechanistic/preclinical only. Tier reflects strongest source.
Primary trials and publications with citation, DOI, study type, and finding summary — enabling direct access to the underlying evidence.
Linked ClinicalTrials.gov entries with phase, status, and population — including completed trials and ongoing studies.
Each agent in the Therapeutics Atlas is structured according to a formal JSON schema, enabling programmatic access, comparison across conditions, and future integration with clinical systems.
The structured data for each condition is available as machine-readable JSON:
This atlas synthesises published evidence as of July 2026. Evidence tiers reflect the best available published evidence per agent-condition pair, not necessarily sufficient evidence for clinical use. T1 RCT data in Long COVID does not always indicate approved indications. All treatment decisions should be made in consultation with qualified healthcare professionals. For conditions like MCAS and ME/CFS where placebo-controlled RCT data is sparse, T2 evidence extrapolated from related conditions forms the evidence base. Trial data should be checked for current status on ClinicalTrials.gov.
Explore biomarker evidence and the full therapeutic pipeline across related conditions.